'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

1:30PoliceofficerscoordinatethesearchforawildanimalinaresidentialareainTeltow,Germany,ThursdayJuly20 ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022




fashion

author:fashion    Page View:7487
Monica Bertagnolli -- Health Policy coverage from STAT
Dr. Monica Bertagnolli speaks during a visit from first lady Jill Biden to the University of California San Francisco Helen Diller Family Comprehensive Cancer Center in San Francisco, Friday, Oct. 7, 2022. (AP Photo/Jeff Chiu, Pool) Jeff Chiu/AP

WASHINGTON — Sen. Bernie Sanders (I-Vt.) will hold a confirmation hearing next month for Monica Bertagnolli, President Biden’s nominee to run the National Institutes of Health, he said Friday.

Sanders, whose health committee oversees the confirmation of the NIH nominee, had refused to hold a hearing on Bertagnolli until the Biden administration promised more drug pricing reform.

advertisement

Newsletters

Sign up for D.C. Diagnosis

An insider's guide to the politics and policies of health care.

Please enter a valid email address. Privacy Policy

HHS announced Friday a deal with Regeneron on the development of the Covid-19 monoclonal antibody. That deal seems to have satisfied Sanders’ demands, though Sanders said the administration must add reasonable pricing provisions to all drugs developed with the help of government funding.

“I welcome the Biden Administration’s announcement today that if Regeneron, through a $326 million contract recently signed with HHS, successfully develops a next generation monoclonal antibody for Covid-19 prevention, the list price of this drug must be equal to or lower than the price in other major countries,” Sanders said in a release.

Sen. Elizabeth Warren (D-Mass.) also had withheld support for Bertagnolli’s nomination until Bertagnolli agreed to Warren’s ethics demands. Bertagnolli agreed to not join the pharmaceutical industry or accept payment from the drug industry, until at least four years after leaving her government position.

advertisement